Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the initiation of dosing of patients in the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study of MDNA11, the Company’s selective, long-acting and novel IL-2 super-agonist.
September 14, 2021
· 6 min read